These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Current and new targets for treating myositis. Moghadam-Kia S; Oddis CV Curr Opin Pharmacol; 2022 Aug; 65():102257. PubMed ID: 35724455 [TBL] [Abstract][Full Text] [Related]
4. Biologic therapy in the idiopathic inflammatory myopathies. Khoo T; Limaye V Rheumatol Int; 2020 Feb; 40(2):191-205. PubMed ID: 31680207 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis. Zhen C; Hou Y; Zhao B; Ma X; Dai T; Yan C Front Immunol; 2022; 13():1051609. PubMed ID: 36578492 [TBL] [Abstract][Full Text] [Related]
7. Idiopathic Inflammatory Myopathies: A Review of the Classification and Impact of Pathogenesis. Mandel DE; Malemud CJ; Askari AD Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28524083 [TBL] [Abstract][Full Text] [Related]
14. Current diagnosis and treatment of polymyositis and dermatomyositis. Sasaki H; Kohsaka H Mod Rheumatol; 2018 Nov; 28(6):913-921. PubMed ID: 29669460 [TBL] [Abstract][Full Text] [Related]
15. Biologics in refractory myositis: experience in juvenile vs. adult myositis; part II: emerging biologic and other therapies on the horizon. Patwardhan A; Spencer CH Pediatr Rheumatol Online J; 2019 Aug; 17(1):56. PubMed ID: 31429786 [TBL] [Abstract][Full Text] [Related]
16. Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies. de Souza FHC; Miossi R; de Moraes JCB; Bonfá E; Shinjo SK Adv Rheumatol; 2018 Sep; 58(1):31. PubMed ID: 30657080 [TBL] [Abstract][Full Text] [Related]
17. Corticosteroids in Myositis and Scleroderma. Postolova A; Chen JK; Chung L Rheum Dis Clin North Am; 2016 Feb; 42(1):103-18, ix. PubMed ID: 26611554 [TBL] [Abstract][Full Text] [Related]